ProCE Banner Activity

Drugs to Shorten COVID-19 Symptom Duration: A Sign of the Times?

Clinical Thought
COVID-19 antiviral agents have shown benefit in reducing not only hospitalization and mortality risk, but also symptom duration and viral load. Are we going to see a shift toward antiviral use in low-risk patients with COVID-19 for the purpose of symptom alleviation?

Released: December 06, 2022

Expiration: December 05, 2023

Share

Faculty

Roger Paredes

Roger Paredes, MD, PhD

Head, Microbial Genomics  
irsiCaixa AIDS Research Institute
Head
Department of Infectious Diseases
Hospital Universitari Germans Trias i Pujol
Badalona, Catalonia, Spain

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by an educational grant from

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Roger Paredes, MD, PhD

Head, Microbial Genomics  
irsiCaixa AIDS Research Institute
Head
Department of Infectious Diseases
Hospital Universitari Germans Trias i Pujol
Badalona, Catalonia, Spain

Roger Paredes, MD, PhD: consultant/advisor/speaker: Gilead, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer.